Teclistamab - Latest Advances

Current experiences with teclistamab in patients with multiple myeloma and renal impairment.

Journal: Expert review of hematology

Published: September 29, 2025

The Two Sides of Bispecific Antibodies in Multiple Myeloma: Where Trial Promise Meets Real-World Practice.

Journal: Blood cancer discovery

Published: August 21, 2025

Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers.

Journal: Seminars in hematology

Published: August 21, 2025

Linvoseltamab (Lynozyfic) for multiple myeloma.

Journal: The Medical letter on drugs and therapeutics

Published: August 12, 2025

Safety and Efficacy of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Proportions from Clinical Trials.

Journal: Cancers

Published: August 05, 2025

Real-World Treatment Patterns and Clinical Outcomes Among Patients With Triple-Class-Exposed and BCMA-Exposed Multiple Myeloma Within the United States.

Journal: EJHaem

Published: August 01, 2025

Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response.

Journal: American journal of hematology

Published: July 30, 2025

EXPRESS: Bispecific T-cell Engagers for Relapsed/Refractory Multiple Myeloma After Solid Organ Transplantation: A Case Series.

Journal: Journal of investigative medicine : the official publication of the American Federation for Clinical Research

Published: July 29, 2025

Defying the Odds: Successful Rescue with Teclistamab in a Case of Ultra-High-Risk Relapsed/Refractory Multiple Myeloma Transforming to Secondary Plasma Cell Leukemia Post-BCMA CAR T Failure.

Journal: Turkish journal of haematology : official journal of Turkish Society of Haematology

Published: July 28, 2025

Real-world patient profile and step-up dosing process of early initiators of teclistamab for multiple myeloma in US hospitals: An analysis using the Premier Healthcare Database.

Journal: Journal of managed care & specialty pharmacy

Published: July 24, 2025

Highlights from the European Hematology Association Congress 2025.

Journal: Acta haematologica

Published: July 21, 2025

Teclistamab-associated cytokine release syndrome in multiple myeloma: a case-based literature review of mechanisms, management, and clinical implications.

Journal: Archive of clinical cases

Published: July 16, 2025

Filters

Current experiences with teclistamab in patients with multiple myeloma and renal impairment.

Current experiences with teclistamab in patients with multiple myeloma and renal impairment.

The Two Sides of Bispecific Antibodies in Multiple Myeloma: Where Trial Promise Meets Real-World Practice.

The Two Sides of Bispecific Antibodies in Multiple Myeloma: Where Trial Promise Meets Real-World Practice.

Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers.

Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers.

Linvoseltamab (Lynozyfic) for multiple myeloma.

Linvoseltamab (Lynozyfic) for multiple myeloma.

Safety and Efficacy of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Proportions from Clinical Trials.

Safety and Efficacy of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Proportions from Clinical Trials.

Real-World Treatment Patterns and Clinical Outcomes Among Patients With Triple-Class-Exposed and BCMA-Exposed Multiple Myeloma Within the United States.

Real-World Treatment Patterns and Clinical Outcomes Among Patients With Triple-Class-Exposed and BCMA-Exposed Multiple Myeloma Within the United States.

Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response.

Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response.

EXPRESS: Bispecific T-cell Engagers for Relapsed/Refractory Multiple Myeloma After Solid Organ Transplantation: A Case Series.

EXPRESS: Bispecific T-cell Engagers for Relapsed/Refractory Multiple Myeloma After Solid Organ Transplantation: A Case Series.

Defying the Odds: Successful Rescue with Teclistamab in a Case of Ultra-High-Risk Relapsed/Refractory Multiple Myeloma Transforming to Secondary Plasma Cell Leukemia Post-BCMA CAR T Failure.

Defying the Odds: Successful Rescue with Teclistamab in a Case of Ultra-High-Risk Relapsed/Refractory Multiple Myeloma Transforming to Secondary Plasma Cell Leukemia Post-BCMA CAR T Failure.

Real-world patient profile and step-up dosing process of early initiators of teclistamab for multiple myeloma in US hospitals: An analysis using the Premier Healthcare Database.

Real-world patient profile and step-up dosing process of early initiators of teclistamab for multiple myeloma in US hospitals: An analysis using the Premier Healthcare Database.

Highlights from the European Hematology Association Congress 2025.

Highlights from the European Hematology Association Congress 2025.

Teclistamab-associated cytokine release syndrome in multiple myeloma: a case-based literature review of mechanisms, management, and clinical implications.

Teclistamab-associated cytokine release syndrome in multiple myeloma: a case-based literature review of mechanisms, management, and clinical implications.